Selecta Biosciences, Inc. EBIT

EBIT of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.

Highlights and Quick Summary

  • EBIT for the quarter ending December 30, 2020 was $-7.9 Million (a -42.49% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT decreased by -58.04%
  • Annual EBIT for 2020 was $-114 Million (a 8.32% increase from previous year)
  • Annual EBIT for 2019 was $-105 Million (a 61.35% increase from previous year)
  • Annual EBIT for 2018 was $-65 Million (a -49.03% decrease from previous year)
  • Twelve month EBIT ending December 30, 2020 was $-56.8 Million (a -7.6% decrease compared to previous quarter)
  • Twelve month trailing EBIT decreased by -4.38% year-over-year
Trailing EBIT for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-56.8 Million $-61.5 Million $-59.6 Million $-59.4 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of Selecta Biosciences, Inc.

Most recent EBITof SELB including historical data for past 10 years.

Interactive Chart of EBIT of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-7.9 $-13.73 $-16.37 $-18.82 $-113.64
2019 $-12.57 $-11.79 $-16.24 $-11.86 $-104.91
2018 $-14.5 $-15.94 $-18.77 $-15.81 $-65.02
2017 $-19.28 $-13.85 $-15.87 $-14.78 $-127.57
2016 $-13.86 $-7.47 $-6.4 $-6.94 $-69.34
2015 $-6.07 $-6.32 $-25.3
2014 $-15.4

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.